TuHURA Biosciences (HURA) vs Voyager Therapeutics (VYGR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Voyager Therapeutics (VYGR) over the past year, losing 26.7% versus a loss of 61.6%. Over five years, VYGR leads with a -49.9% price change compared with -99.9% for HURA. Voyager Therapeutics is the larger company by market cap ($117.1 million vs $112.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | VYGR |
|---|---|---|
| Share price | $1.76 | $1.90 |
| Market cap | $112.16M | $117.07M |
| 1-day change | -3.83% | -7.77% |
| YTD return | +132.50% | -51.65% |
| 1-year return | -26.67% | -61.62% |
| 5-year return | -99.89% | -49.87% |
| EPS (TTM) | $-0.54 | $-1.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $40.37M |
| Revenue growth (YoY) | — | -49.53% |
| Net income (latest FY) | $-30.05M | $-119.72M |
| Operating margin | — | -326.56% |
| Net margin | — | -296.53% |
| 52-week high | $3.43 | $5.48 |
| 52-week low | $0.41 | $1.89 |
| Distance from 52-week high | -48.69% | -65.33% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +356.82% | +683.68% |
| Average volume | 221.74K | 578.54K |
| Shares outstanding | 63.73M | 61.62M |
| Employees | 22 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed VYGR by 34.9 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Voyager Therapeutics
VYGR stock →Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
HURA vs VYGR FAQ
Which is bigger, TuHURA Biosciences or Voyager Therapeutics?
Voyager Therapeutics (VYGR) is larger, with a market capitalization of $117.07M compared with $112.16M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or VYGR?
HURA returned -26.67% over the past 12 months, compared with -61.62% for VYGR (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Voyager Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for TuHURA Biosciences and Biotechnology: Biological Products (No Diagnostic Substances) for Voyager Therapeutics.